JP Morgan Chase
CRBP icon

JP Morgan Chase’s Corbus Pharmaceuticals CRBP Stock Holding History

JP Morgan Chase’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-103
Closed -$6K – 5668
2020
Q3 		$6K Buy
+103
New +$18.7K ﹤0.01% 5310
2020
Q2 		– Sell
-447
Closed -$70K – 5414
2020
Q1 		$70K Hold
447
– – ﹤0.01% 4625
2019
Q4 		$73K Buy
+447
New +$66.1K ﹤0.01% 5000
2019
Q2 		– Sell
-130
Closed -$27K – 5790
2019
Q1 		$27K Hold
130
– – ﹤0.01% 5325
2018
Q4 		$23K Buy
+130
New +$25.9K ﹤0.01% 5292

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

JP Morgan Chase's CRBP Position: Q3 2025 in Review

JP Morgan Chase sold out of Corbus Pharmaceuticals (CRBP) in Q3 2025, closing a stake of 983 shares — an estimated $6.78K sold.

JP Morgan Chase first reported a position in CRBP in Q2 2016 and held it in 32 quarters. The position peaked at $2.42M in Q1 2024. 81 funds tracked by Wall St. Rank hold CRBP as of Q3 2025.

  • JP Morgan Chase reported no remaining Corbus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 983 Corbus Pharmaceuticals shares in Q3 2025, an estimated $6.78K.
  • JP Morgan Chase first reported a position in Corbus Pharmaceuticals in Q2 2016 and held it in 32 quarters.
  • JP Morgan Chase's Corbus Pharmaceuticals position peaked at $2.42M in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.